About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 

Read More

Current Issue

Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Published: 2023-03-13

In-Depth Reviews

Neonatal Lupus Erythematosus: A Case Report and Review of the Literature

Taylor Bullock, Robert Simonds, Jeffrey McBride, Mawish Irfan, Sarah Young

Page 649-656

Original Research

Research Letters

Perspectives on Pediatric Hidradenitis Suppurativa Care: A Survey of Pediatric Providers

Rahul Masson, Terri Shih, Devea De, Swetha Atluri, Shahram Yazdani, Christopher J. Sayed, Vivian Y. Shi, Jennifer Lin Hsiao

Page 681-685

Brief Articles

Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3

Boni Elewski, Matthew Zirwas, Azra Kurbasic, Shannon Schneider, Ami Claxton, Jonathan Silverberg

Page 686-695

Cutaneous Acanthamoeba Infection Presenting with Granulomatous Vasculitis

Meredith Park, Paul Googe, Vimal K Derebail, Manish K Saha, Eduard Matkovic, Jennifer Cope, Ibne Karim , Carolyn Ziemer, Sam Wu

Page 700-704

Petaloid Seborrheic Dermatitis: A Variant Described Primarily in Skin of Color

Rachel Christensen, Colleen Powers, Chelsea Mockbee, Robert Brodell

Page 705-709

Characterizing Skin Cancers Arising for the First Time Following Solid Organ Transplant with Subsequent Recurrence

Chelsea Shope, Laura Andrews, Courtney Linkous, Hannah Neimy, Lara Wine Lee

Page 714-718

Linear Depigmented Macules and Patches in an Elderly Man

Maansi Kulkarni, Sean Igelman, Julian Trevino, Clayton Conner

Page 719-722

Perioral Contact Dermatitis Caused by Limonene Hydroperoxide in Cannabis Vaping Products

Kevin Mai, Quang D. Pham, Joseph Haquang, Diem Q. Pham DO

Page 723-726

Short Communications

Acneiform Eruption of Monkeypox in a Pilot

Faraz Yousefian, Christopher Kowalczyk, Nevada Norris, Carlos Ricotti, Francisco Kerdel

Page 732-735

Treatment of Cutaneous Lesions in a Case of Blue Rubber Bleb Nevus Syndrome

Sokhna Seck, Taylor Bullock, Shilpi Khetarpal

Page 740-742

Compelling Comments

At-Home Microneedling of Acral Skin to Increase Percutaneous Absorption of Imiquimod

Kate Beekman, Danielle DePalo, James Grichnik, Lilia Correa, Jonathan Zager

Page 743-744

SKINmages: Clinical Images in Dermatology

Successful Treatment of Morphea with Topical Ruxolitinib

McKenzie A. Dirr, Avi Bitterman, Roudha Al-Dehneem, Alice B. Gottlieb

Page 747-749

A Friable, Polypoid Tumor on the Chest

Catherine Motosko, Gabriel Villada, Fleta Bray, Gregory Perez

Page 750-751

Posters from 2023 WCH Dermatology Conference: Psoriasis

Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study

Loretta Fiorillo, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Susana Armesto, Peter Maes, Rajneet Oberoi, Maria Paris, Wendy Zhang, Zuoshun Zhang, Lisa Arkin

Page s109

Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study

Joseph Merola, Lawrence Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Petra Staubach, Sue Cheng, Shauna Jardon, Maria Paris, Mindy Chen, Kim Papp

Page s110

Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial

Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, David Adam, H. Chih-ho Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David Berk

Page s111

Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years

April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov

Page s112

Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy

Sang Hee Park, Yichen Zhong, Adam Sima, Vardhaman Patel, Joe Zhuo, Carla Roberts-Toler, Brandon Becker, Sara Hovland, Bruce Strober

Page s113

Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study

Victoria P. Werth, Marilyn Pike, Joan T. Merrill, Eric Morand, Ronald van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

Page s114

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Mark Lebwohl, Alexander Egeberg, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Bruce Strober

Page s116

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths

Page s117

Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt

Page s118

Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program

Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi

Page s119

Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

David Burden, Yukari Okubo, Min Zheng, Diamant Thaci, Peter van de Kerkhof, Na Hu, Christian Thoma, Siew Eng Choon

Page s121

Global consensus on the clinical course, treatment and management of generalized pustular psoriasis (GPP)

Lluis Puig, Siew Eng Choon, Alice Gottlieb, Slaheddine Marrakchi, Jörg Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda Gooderham

Page s122

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Linda Stein Gold, Christopher E. M. Griffiths, Anna Tallman, Philip M. Brown, Mark G. Lebwohl

Page s123

Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial

Bruce Strober, Joshua A. Zeichner, Seemal R. Desai, Michael Cameron, Jennifer Cather, Matthew J. Bruno, David S. Rubenstein, Anna Tallman, Philip M. Brown

Page s125

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis

Leon Kircik, Mathew Zirwas, Shawn G. Kwatra, Michael Lewitt, Holly Glover, Tomas Chao, Philip M. Brown, David S. Rubenstein, Anna Tallman

Page s126

Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Linda Stein Gold, Andreas Pinter, April Armstrong, Lars Iversen, Morten Praestegaard, Matthias Augustin

Page s128

Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials

Alexa B Kimball, Afsaneh Alavi, Gregor BE Jemec, Alice Gottlieb, Xiaoling Wei, Magdalena B Wozniak, Lorenz Uhlmann, Angela Llobet Martinez, Deborah Keefe, Ruvie Martin, Li Chen, Elisa Muscianisi

Page s129

Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety

Lawrence Green, Jerry Bagel, George Han, Abby Jacobson, Martha Sikes

Page s130

Brodalumab: 4-Year US Pharmacovigilance Report

Mark Lebwohl, Andrea Murina, George Han, Abby Jacobson

Page s132

Atopic Dermatitis

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

James Del Rosso, Scott Guenthner, Chih-ho Hong, John E Jett, Philip M. Brown, David S. Rubenstein, Stephen Piscitelli

Page s137

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Amy Paller, Adelaide A. Hebert, John E Jett, Philip M. Brown, David S. Rubenstein, Stephen Piscitelli

Page s138

The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy Paller, Jonathan Silverberg, H. Chih ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric Simpson

Page s139

Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Michael Cork, Carsten Flohr, Anthony Bewley, Andrew Blauvelt, Chih-ho Hong, Shinichi Imafuku, Marie L.A. Schuttelaar, Eric Simpson, Weily Soong, Petra Amoudruz, Katja Wendicke Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Amy Paller

Page s140

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Page s141

3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis

Richard Warren, Kristian Reich, Eric Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Anna Carlsson, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt

Page s142

Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest

Kristian Reich, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, Andrew Blauvelt

Page s143

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Page s144

Real World Baseline Characteristics and Early Patient Reported Outcomes in Adult Patients with Moderate to Severe Atopic Dermatitis Treated with Tralokinumab

Peter Lio, Yestle Kim, Sanjeev Balu, Adriana Guana, Dawn Bates, deMauri Mackie, Halley Costantino, Amanda Lopez, Jennifer Soung

Page s145

Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe

Lawrence Eichenfield, Vivian Shi, JiaDe Yu, Evangeline Pierce, Amber Reck Atwater, Jenny Austin, Phoebe Salmon, James Piercy, Peter Anderson, Amy Paller

Page s146

Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis

James Q. Del Rosso, Pearl Kwong, Iftikhar Hussain, Sebastien Barbarot, Jose Manuel Carrascosa, Maria Jose Rueda, Amber Reck Atwater, Hany Elmaraghy, Luna Sun, Sherry Chen, Chitra Natalie, Stephan Weidinger

Page s147

Impact Of Day-to-Day Sleep Disruption on The Burden of Disease In Moderate-severe Adult Atopic Dermatitis Patients

Evangeline Pierce, C. Elise Kleyn, Susanne Grond, Jenny Austin, Catherine Reed, Sonja Ständer

Page s148

Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry

Michael Haft, Keith Knapp, Ami Claxton, Breda Munoz, Sanjeev Balu, Shannon Schnieder, Jonathan Silverberg, Diamant Thaci, Lawrence Eichenfield

Page s149

Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

Eric L. Simpson, Johnathan Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary L. Chan, Justine Alderfer, William Romero, Susan Johnson

Page s150

Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis

Jacob P. Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Brian S. Kim, Pinaki Biswas, Gary L. Chan, Daniela E. Myers, Melissa Watkins, Justine Alderfer, Erman Güler, Jonathan I. Silverberg

Page s151

Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN

Jonathan I. Silverberg, Mark Boguniewicz, Kim Papp, Athanasios Tsianakas, Pinaki Biswas, Claire Feeney, Mark Levenberg

Page s152

Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study

Vivian Shi, Tina Bhutani, Mette Deleuran, Luz Fonacier, Stephen Shumack, Fan Zhang, Michael C. Cameron, Gary L. Chan, Hernan Valdez, Natalie Yin

Page s153

Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Zakiya Rice, Melinda Gooderham, Mark G. Lebwohl, Eric L. Simpson, Mark Boguniewicz, Andreas Wollenberg, Irina Lazariciu, Gary L. Chan, Justine Alderfer, Melissa Watkins

Page s154

Acne & Rosacea

Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among pediatric patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S: PROSES study

Adelaide Hebert, Evan Rieder, Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Leon Kircik, Andrew F. Alexis, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Richard G. Fried

Page s155

Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age

Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Andrew F. Alexis, Richard G. Fried, Evan Rieder, James Del Rosso, Leon Kircik, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Adelaide Hebert

Page s156

Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication

Hilary Baldwin, James Del Rosso, Leon Kircik, Linda Stein Gold, Adelaide Hebert, Evan A. Rieder, Andrew F. Alexis, Julie C. Harper, Richard G. Fried, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Emmy Graber

Page s157

Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug

Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Michael Gold, MD, Zoe D. Draelos, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD

Page s159

Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris

Lawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti

Page s160

Skin Cancer

Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

Leon Kircik, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s161

Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)

Todd Schlesinger, Leon Kircik, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s162

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

Georgina V. Long, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaëlle Quéreux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, John M. Kirkwood

Page s163

A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence

Aaron S Farberg, Kelli L Ahmed, Briana B Rackley, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Sarah J Kurley, Matthew S Goldberg

Page s166

Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma

Brian Martin, Christine Bailey, Matthew Goldberg, Valentina Petkov, Robert Cook, Kyle Covington, Sarah Kurley

Page s167

Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study

J. Michael Guenther, Christine N. Bailey, Kelli Ahmed, Clare Johnson, Brian Martin, Sarah Kur, Maki Yamamoto

Page s168

Genomic Profiling of Lentigo Maligna within an Interim Registry Analysis​

Greg Stevens, James Rock, Burkhard Jansen, Terry Arnold, Jennifer Wood, Loren Clarke, Mark Hyde

Page s169

Visual Assessment and Dermoscopy Enhanced by Non-invasive Genomic Testing

Sarah Matthews, Gary Peck, Rachel Reifer, Mark Hyde, Burkhard Jansen, Maral Skelsey

Page s171

Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model

Nancy Messier, PhD, Frédéric Couture, PhD, Vanessa Théberge, MSc, Mario Harvey, MSc, Kenneth Kobayashi, MD FRCPC FAAD

Page s172

C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma

Danny Rischin, Daniel Brungs, Fiona Day, Hayden Christie, Vishal Patel, Gerard Adams, James Estes Jackson, Maite De Liz Vassen Schurmann, Dmitry Kirtbaya, Thuzar Shin, Christopher Hart, Elizabeth Stankevich, Siyu Li, Israel Lowy, Hyunsil Han, Priscila Gonçalves, Matthew Fury, Sandro Porceddu

Page s173

CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

Guilherme Rabinowits, Jade Homsi, Soo Park, Nikhil Khushalani, Timothy Panella, David Ellison, Rhonda Gentry, Suraj Venna, John Strasswimmer, Richard Zuniga, Sunandana Chandra, Emily Ruiz, Michael Migden, Sherrif Ibrahim, Nikita Mehta, Timothy Inocencio, Xuanyao He, Haixin Zhang, Kathryn Gillis, Jean-Francois Pouliot

Page s174

Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Brett Hughes, Jean-Jacques Grob, Samantha Bowyer, Fiona Day, Rahul Ladwa, Brian Stein, Eva Muñoz-Couselo, Nicole Basset-Seguin, Alexander Guminski, Laurent Mortier, Axel Hauschild, Michael Migden, Chrysalyne Schmults, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin

Page s175

Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3

Michael Migden, Chrysalyne Schmults, Nikhil Khushalani, Alexander Guminski, Anne Lynn Chang, Karl Lewis, George Ansstas, Samantha Bowyer, Brett Hughes, Dirk Schadendorf, Badri Modi, Lara Dunn, Lukas Flatz, Axel Hauschild, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin

Page s176

Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors

Karl D Lewis, Ketty Peris, Aleksandar Sekulic, Alexander J Stratigos, Lara Dunn, Zeynep Eroglu, Anne Lynn S Chang, Michael R Migden, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Emmanuel Okoye, Jean-François Baurain, Oliver Bechter, Axel Hauscild, Marcus O Butler, Leonel Hernandez-Aya, Lisa Licitra, Rogerio I Neves, Emily S Ruiz, Frank Seebach, Israel Lowy, Priscila Goncalves, Matthew G Fury

Page s177

Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up

Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stéphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Suk-Young Yoo, Ebony Coates, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Israel Lowy, Matthew G Fury

Page s178

Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

Omid Hamid, Karl Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Nehal J Lakhani, John Kaczmar, Ragini Kudchadkar, Alexander Spira, Guilherme Rabinowits, Kevin Kim, Richard Carvajal, Stephen Williamson, Ella Ioffe, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Laura Brennan, Glenn Kroog, Tasha Sims, Israel Lowy, Giuseppe Gullo

Page s179


Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib

Brett King, Jerry Shapiro, Manabu Ohyama, Alexander Egeberg, Yves Dutronc, Yun-Fei Chen, Wen-Shuo Wu, Yuxin Ding, Najwa Somani, Rodney Sinclair

Page s184

Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program

Maryanne Senna, Ohsang Kwon, Bianca Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Brett King

Page s185

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

Bianca Maria Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi

Page s186

Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ulrike Blume-Peytavi, Walter Gubelin Harcha, Qinping Yang, George Schmieder, Maria Hordinsky, Giuseppe Micali, Manabu Ohyama, Liza Takiya, Fan Zhang, Gregor Schaefer, Robert Wolk, Urs Kerkmann

Page s187

Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel Zwillich, Helen Tran , Fan Zhang, Liza Takiya

Page s188

Disorders of Pigmentation

Efficacy of a Targeted Pigment-Correcting Spot Treatment Cream for Post-inflammatory Hyperpigmentation and Solar Lentigines in a 12-Week, Single-Center Clinical Study

Elizabeth T. Makino, BS, CCRA, MBA, Priscilla Huang, BA, Summer F. Acevedo, PhD, Cristiane de Oliveira, PhD, Rahul C. Mehta, PhD

Page s189


Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases

Olga Ostrovskaya, Magdalena Sips, Peter Ulrichts, Lance Trainor, Peter Verheesen, Ivaylo Stoykov

Page s193

Tapinarof Inhibits the Formation, Cytokine Production, and Persistence of Resident Memory T Cells In Vitro

Nathan Mooney, Jessica E. Teague, Ahmed E. Gehad, Kimberly McHale, David S. Rubenstein, Rachael A. Clark

Page s194

Efinaconazole in the Age of Antifungal Resistance

Ahmed Gamal, Mohammed Elshaer, Lisa Long, Thomas S. McCormick, Boni Elewski, Mahmoud A. Ghannoum

Page s195


Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial

Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu

Page s196

Survey Results Identifying Clinician Strategies for Therapy Selection for Common Inflammatory Skin Diseases

Nicholas D. Brownstone, Aaron S. Farberg, Ann P. Quick, Jennifer J. Siegel, Matthew S. Goldberg, Peter A. Lio

Page s197

Non-Invasive Genomic Profiling in Pediatric Patients

Allyson Perry, Danielle Ruppenthal, Kellie Hill

Page s198

Quality of Information on Molluscum Contagiosum Consumer Websites

Elaine Siegfried , Samantha Ong, Jennifer Andres, Christine Crosby, Melissa Olivadoti

Page s200

View All Issues